News

Video

Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D

Author(s):

Shuo Ma, MD, PhD

Preliminary results for treatment with zanubrutinib + venetoclax in patients with high-risk TN CLL/SLL with del(17p) and/or TP53 mutation showed Promising efficacy in a high-risk population with deep and durable responses according to data from arm D of the phase 3 SEQUOIA trial (NCT03336333).

Related Videos
Grzegorz S. Nowakowski, MD
John Seymour, MBBS, FRACP, PhD
Reid Merryman, MD
Partow Kebriaei, MD
Jean L. Koff, MD, MS
Sonali M. Smith, MD
Naval G. Daver, MD,
A panel of 5 experts on CLL
A panel of 5 experts on CLL
Andrew Hantel, MD
Related Content
William G. Wierda, MD, PhD
September 6th 2024

Liso-Cel Elicits Consistent Responses in R/R CLL/SLL, Irrespective of High-Risk Features

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Leonard Mazur, CEO, Citius Pharma, Citius Oncology
September 6th 2024

NCCN Adds Denileukin Diftitox to CTCL Clinical Practice Guidelines in Oncology

Matthew Lunning, DO, FACP
November 30th 2023

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

Reid W. Merryman, MD
September 5th 2024

Novel Cell-Free DNA Assays Expand the Reach of MRD Detection in Lymphoma

Rayne Helen Rouce, MD, BS, Baylor College of Medicine
September 4th 2024

Tisagenlecleucel Climbs into Earlier Lines of Therapy for Pediatric R/R B-ALL